NEW YORK, June 23 (GenomeWeb News) - Althea Technologies said today that it has received a Phase I Small Business Innovation Research grant from the National Institutes of Health, by way of the National Institute on Deafness and Other Communication Disorders, to develop a low cost mechanism for translating gene-expression-based research in toxicology into validated, high-throughput, expression screens for the assessment of a range of different toxicological and disease mechanistic endpoints.
The amount of the funding was not disclosed.
The approach will use Althea's eXpress Profiling technology, a high-throughput, highly-multiplexed, quantitative RT-PCR-based gene expression analysis technique, which was recently licensed to Beckman Coulter.
The new grant will focus on the development and validation of gene sets and predictive classifiers for specific and important toxicological endpoints. Althea's aim is to provide a roadmap for translating microarray-based discoveries into high throughput, low cost assays and validating their use in the drug discovery and development processes, the company said.